Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

Ads

You May Also Like

Hemostemix Formalizes World-Class Scientific Advisory Board

CALGARY, Alberta, July 05, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) ...